Menu Search
Equities

Stratec Se

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0RAR:LSE

Stratec Se

Actions
  • Price (EUR)21.10
  • Today's Change0.300 / 1.44%
  • Shares traded596.00
  • 1 Year change-42.09%
  • Beta0.7681
Data delayed at least 20 minutes, as of Feb 06 2026 15:47 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Stratec SE is a Germany-based company. The Company is engaged in development and manufacture of analyzer systems, and it is also performing and managing administrative and organizational tasks for laboratory markets. Stratec is providing automation solutions and instrumentation of biochemical processes using hardware and software for in-vitro diagnostics and life science companies. It also developing and integrating instrumentation, complex consumables and software by covering virtually the entire value chain for specification, design, manufacture and approval of complex analyzer system solutions.

  • Revenue in EUR (TTM)256.91m
  • Net income in EUR15.65m
  • Incorporated2018
  • Employees1.42k
  • Location
    Stratec SeGewerbestr. 37BIRKENFELD 75217GermanyDEU
  • Phone+49 708279160
  • Fax+49 70 827916999
  • Websitehttps://www.stratec.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.